Wuhan Hiteck Biological Pharma Co.,Ltd (300683.SZ) SHZ

Currency In CNY

AD

Wuhan Hiteck Biological Pharma Co.,Ltd

Address

Hite Science and Technology Park

Wuhan, 430056

China

Phone

86 27 8489 1666

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

1520

First IPO Date

August 08, 2017

Key Executives

NameTitlePayYear Born
Kun YangSecretary of Board of Directors01987
Sheng Qiang LiDeputy General Manager01976
Huang ChenDeputy GM & Director01975
Wen XianFinancial Director, Accounting Supervisor & Non-Independent Director01975
AD

Description

Wuhan Hiteck Biological Pharma Co.,Ltd is a biopharmaceutical enterprise operating in China, primarily engaged in the research, development, manufacturing, and commercialization of bio-engineered products and lyophilized injectable medications. The company's extensive product portfolio encompasses a variety of pharmaceutical solutions, such as Jinlujie, a mouse nerve growth factor for injection; omeprazole sodium for injection; cyclic adenosine phosphate; Xinye acyclovir tablets; Bingbing Horse & Dragon, an indomethacin furazolidone suppository; Xunkeyuan tinidazole suppository; and Shufu nimodipine sustained-release tablets. Beyond therapeutics, Wuhan Hiteck also provides a comprehensive array of diagnostic kits. These include tests for measles virus and rubella virus nucleic acid, mycoplasma isolation and identification, bacterial vaginosis rapid detection, measles virus IgG antibodies, and the coronavirus N-protein. Furthermore, the firm supplies active pharmaceutical ingredients (APIs) and their chemical intermediates, notably Lopinavir and Ritonavir. Its core therapeutic areas of focus are the nervous system and oncology. Established in 1992, Wuhan Hiteck Biological Pharma Co.,Ltd is headquartered in Wuhan, China.

AD